Form 8-K

8-K — LEMAITRE VASCULAR INC

Accession: 0001193125-26-332982

Filed: 2026-08-04

Period: 2026-08-04

CIK: 0001158895

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — d320964d8k.htm (Primary)

EX-99.1 (d320964dex991.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d320964d8k.htm · Sequence: 1

8-K

LEMAITRE VASCULAR INC false 0001158895 0001158895 2026-08-04 2026-08-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 4, 2026

LeMaitre Vascular, Inc.

(Exact name of registrant as specified in its charter)

Commission File Number: 001-33092

Delaware

04-2825458

(State or other jurisdiction

of incorporation)

(IRS Employer

Identification No.)

63 Second Avenue

Burlington, MA 01803

(Address of principal executive offices, including zip code)

781-221-2266

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class

Trading

symbol

Name of exchange

on which registered

Common stock, $0.01 par value per share

LMAT

The Nasdaq Global Market

Indicate by checkmark whether the company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.

Results of Operations and Financial Condition.

On August 4, 2026, LeMaitre Vascular, Inc. (the “Company”) issued a press release regarding its preliminary financial and operational results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Report.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Disclaimer on Forward-Looking Statements

This current report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include risks and uncertainties included under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

Item 9.01.

Financial Statements and Exhibits.

The following exhibits are furnished or filed as part of this Report, as applicable:

(d)

Exhibits.

Exhibit

No.

Description

99.1

Press release issued by LeMaitre Vascular, Inc. on August 4, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

Signature(s)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LeMaitre Vascular, Inc.

Date: August 4, 2026

By:

Dorian P. LeBlanc

/s/ DORIAN P. LEBLANC

Chief Financial Officer

Exhibit Index

Exhibit

No.

Description

99.1

Press release issued by LeMaitre Vascular, Inc. on August 4, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

EX-99.1

Filename: d320964dex991.htm · Sequence: 2

EX-99.1

Exhibit 99.1

LeMaitre Q2 2026 Financial Results

BURLINGTON, MA, August 4, 2026 – LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today

reported Q2 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance.

Q2 2026:

•

Sales $70.4mm, +10% (+10% organic) vs. Q2 2025

•

Gross margin 72.1% (+210 bps)

•

Op. income $20.4mm (+26%)

•

Op. margin 29%

•

EPS $0.74 (+23%)

•

Cash up $9.0mm sequentially to $376.2mm

Artegraft sales increased 34% in the quarter. Grafts (+23%), carotid shunts (+18%), and patches (+4%) each posted records, as did EMEA (+18%), APAC (+18%) and

the Americas (+5%). Catheters were down 11% in the quarter due to recall-driven overstocking in Q2 2025. Q2 organic growth was 12% excluding catheters.

Gross margin of 72.1% was up 210 bps due to higher prices, mix shift, and operational efficiencies. Operating income of $20.4mm (+26%) also benefited from

headcount restraint: 660 at 6/30/2026 vs. 658 at 6/30/2025.

Chairman/CEO George LeMaitre said, “Our focus on the Artegraft international launch

paid off in Q2. The product is now approved in 56 countries, accounting for 21% of sales. So our largest product is now our fastest-growing product. To underpin the Artegraft launch and pave the way for RFA, we continue to build our sales force, go

direct in new countries and we’re now undertaking six international warehouse expansions. $376m of cash provides strategic optionality.”

Business Outlook

Q3 2026 Guidance

Q4 2026 Guidance

Full Year Guidance

Sales

$66.3mm - $68.3mm

(Mid $67.3mm, +10%, +11% org.)

$71.1mm - $73.1mm

(Mid $72.1mm, +12%, +12% org.)

$274.3mm - $278.3mm

(Mid $276.3mm, +11%, +11% org.)

Gross Margin

72.2%

72.6%

72.4%

Op. Income

$17.3mm - $18.8mm

(Mid $18.1mm, -11%, +7% adj.)

$19.8mm - $21.2mm

(Mid $20.5mm, +9%)

$75.3mm - $78.2mm

(Mid $76.8mm, +13%, +19% adj.)

Op. Margin (Mid)

27%

29%

28%

EPS

$0.66 - $0.71

(Mid $0.69, -9%, +11% adj.)

$0.75 - $0.81

(Mid $0.78, +15%)

$2.84 - $2.94

(Mid $2.89, +15%, +21% adj.)

Q3 2025 results included a non-recurring benefit from the Employee

Retention Tax Credit. Non-GAAP adjusted figures exclude this benefit. A reconciliation of GAAP to non-GAAP projected results is included.

Quarterly Dividend

On July 28, 2026, the

Company’s Board of Directors approved a quarterly dividend of $0.25/share of common stock. The dividend will be paid on September 3, 2026, to stockholders of record on August 20, 2026.

Share Repurchase Program

On February 19, 2026, the

Company’s Board of Directors authorized the repurchase of up to $100.0mm of the Company’s common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 18, 2027, unless extended by

the Board.

Conference Call Reminder

Management will conduct a conference call at 5:00pm ET today. The conference call will be broadcast live over the Internet. Individuals interested in

listening to the webcast can log on to the Company’s website at www.lemaitre.com/investor. Access to the live call is available by registering online here. All registrants will receive

dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor. For individuals unable to

join the live conference call, a replay will be available on the Company’s website.

A reconciliation of GAAP to

non-GAAP results is included in the tables attached to this release.

About LeMaitre

LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than

200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.

LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.

For more information about the Company, please visit www.lemaitre.com.

Use of Non-GAAP Financial Measures

LeMaitre management believes that in order to better understand the Company’s short- and long-term financial trends, investors may wish to consider

certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a

comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing

operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, GAAP financial performance measures. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.

In this press release,

the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events. The Company refers to the

calculation of non-GAAP sales growth percentages as “organic” or “adjusted.” The Company analyzes non-GAAP sales on a constant currency basis,

net of acquisitions and other non-recurring events. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions,

divestitures, product discontinuations, factory closures, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency

basis net of such transactions provides an additional and meaningful assessment of sales to management. Additionally, the Company has provided percentages for operating income and EPS guidance adjusted to exclude the effects of the employee

retention tax credit received in 2025. Management believes that viewing projected growth in operating income and EPS excluding those effects provides an alternative and meaningful view of the Company’s projected profitability.

Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly

comparable GAAP financial measures set forth in the tables captioned “Reconciliation of GAAP to Non-GAAP Financial Measures” below.

Forward-Looking Statements

The Company’s current

financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.

Statements in this press release regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s

current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, our ability to maintain historic levels of profit growth; our ability to

increase the selling prices of our products; the status of our regulatory approvals, compliance with regulatory requirements, and the potential for adverse regulatory findings or enforcement actions arising from inspections, audits, or other

regulatory reviews, affecting our ability to market and sell our products domestically and internationally; competition from other medical device companies and alternative medical technologies; our ability to source, acquire, and integrate

acquisitions; our dependence on sole- or limited-source suppliers; our ability to engage sales call points other than vascular surgeons; disruptions to our information technology systems or breaches of our information security systems; our

implementation of our new enterprise resource planning system; our ability to procure, process, and preserve human tissue and comply with relevant regulatory requirements; the impact of a disruption in our manufacturing facilities; our ability to

navigate the risks inherent in operating internationally; our ability to transition to direct sales models in certain international territories; the occurrence of litigation relating to product liability, employment matters, intellectual property,

contract disputes, and other matters; the occurrence of

product defects or recalls; our ability to service and repurchase our debt; the dilutive effect of a conversion of our debt; our ability to navigate executive officer transitions and retain key

personnel; our ability to protect our intellectual property; volatility in the price of our common stock; and other risks and uncertainties included under the heading “Risk Factors” in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, which are all available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website

at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new

information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

CONTACT:

Gregory Manker

Director of Business Development and Investor

Relations

ir@LEMAITRE.COM

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

CONDENSED CONSOLIDATED BALANCE SHEETS

(amounts in

thousands)

June 30, 2026

December 31, 2025

(unaudited)

Assets

Current assets:

Cash and cash equivalents

26,625

28,244

Short-term marketable securities

349,615

330,876

Accounts receivable, net

35,682

33,610

Inventory and other deferred costs

70,503

70,422

Prepaid expenses and other current assets

5,872

5,080

Total current assets

488,297

468,232

Property and equipment, net

29,591

26,997

Right-of-use

leased assets

19,998

15,762

Goodwill

65,945

Other intangibles, net

30,544

33,089

Deferred tax assets

734

759

Other assets

5,440

4,906

Total assets

640,549

615,690

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

3,236

3,646

Accrued expenses

22,880

29,411

Acquisition-related obligations

380

322

Lease liabilities - short-term

3,439

2,944

Total current liabilities

29,935

36,323

Convertible senior notes, net

169,091

168,645

Lease liabilities - long-term

17,724

14,003

Deferred tax liabilities

1,998

1,735

Other long-term liabilities

1,459

1,468

Total liabilities

220,207

222,174

Stockholders’ equity

Common stock

245

244

Additional paid-in capital

236,161

228,407

Retained earnings

206,017

184,715

Accumulated other comprehensive loss

(4,165

)

(2,411

)

Treasury stock

(17,916

)

(17,439

)

Total stockholders’ equity

420,342

393,516

Total liabilities and stockholders’ equity

640,549

615,690

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(amounts

in thousands, except per share amounts)

(unaudited)

For the three months ended

For the six months ended

June 30, 2026

June 30, 2025

June 30, 2026

June 30, 2025

Net sales

70,382

64,232

136,933

124,103

Cost of sales

19,618

19,258

37,773

37,709

Gross profit

50,764

44,974

99,160

86,394

Operating expenses:

Sales and marketing

14,408

14,895

28,923

29,107

General and administrative

11,110

10,396

23,156

20,883

Research and development

4,847

3,541

8,907

7,636

Total operating expenses

30,365

28,832

60,986

57,626

Income from operations

20,399

16,142

38,174

28,768

Other income (expense):

Investment income

3,386

2,980

6,710

5,883

Interest expense

(1,302

)

(1,299

)

(2,602

)

(2,589

)

Other income (loss), net

(294

)

247

(421

)

249

Income before income taxes

22,189

18,070

41,861

32,311

Provision for income taxes

5,139

4,291

9,132

7,521

Net income

17,050

13,779

32,729

24,790

Earnings per share of common stock

Basic

0.75

0.61

1.43

1.10

Diluted

0.74

0.60

1.42

1.08

Weighted - average shares outstanding:

Basic

22,858

22,614

22,830

22,592

Diluted

24,531

22,892

24,505

22,896

Cash dividends declared per common share

0.25

0.20

0.50

0.40

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(amounts

in thousands)

(unaudited)

For the six months ended

June 30, 2026

June 30, 2025

Operating activities

Net income

32,729

24,790

Adjustments to reconcile net income to net cash provided by operating activities

Depreciation and amortization

5,285

5,200

Stock-based compensation

4,027

3,990

Amortization of issuance costs on convertible notes

446

433

Non-cash investment income

(805

)

—

Provision for inventory write-downs

1,548

1,030

Provision for credit losses

333

337

Foreign currency transaction effect on income

145

(279

)

Changes in operating assets and liabilities:

Accounts receivables

(2,877

)

(5,299

)

Inventory and other deferred costs

(1,935

)

(3,454

)

Prepaid expenses and other assets

(1,363

)

1,676

Accounts payable and other liabilities

(6,475

)

(1,250

)

Accrued interest

—

2,156

Net cash provided by operating activities

31,058

29,330

Investing activities

Purchases of short-term marketable securities

(231,434

)

(17,849

)

Purchases of property and equipment

(5,096

)

(2,725

)

Payments related to acquisitions, net of cash acquired

(158

)

(95

)

Proceeds from short-term marketable securities

212,489

—

Net cash used in investing activities

(24,199

)

(20,669

)

Financing activities

Proceeds from stock option exercises

3,728

3,072

Deferred payments for acquisitions

(95

)

(1,433

)

Payment of withholding taxes in connection with net settlement of equity awards

(477

)

(605

)

Common stock cash dividend paid

(11,427

)

(9,037

)

Net cash used in financing activities

(8,271

)

(8,003

)

Effect of exchange rate changes on cash and cash equivalents

(207

)

909

Net (decrease) increase in cash and cash equivalents

(1,619

)

1,567

Cash and cash equivalents at beginning of period

28,244

25,610

Cash and cash equivalents at end of period

26,625

27,177

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

SELECTED NET SALES INFORMATION

(amounts in thousands)

(unaudited)

For the three months ended

For the six months ended

June 30, 2026

June 30, 2025

June 30, 2026

June 30, 2025

Net Sales by Geography

Americas

43,454

41,321

85,050

80,279

Europe, Middle East and Africa

22,137

18,840

42,424

35,799

Asia Pacific

4,791

4,071

9,459

8,025

Total Net Sales

70,382

100

64,232

100

136,933

100

124,103

100

LEMAITRE VASCULAR, INC (NASDAQ: LMAT)

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

(amounts in thousands)

(unaudited)

For the three months ended

For the six months ended

June 30, 2026

June 30, 2025

June 30, 2026

June 30, 2025

Reconciliation between GAAP and Non-GAAP Adjusted

EBITDA

Net income as reported

17,050

13,779

32,729

24,790

Interest (income) expense, net

(2,084

)

(1,681

)

(4,108

)

(3,294

)

Amortization and depreciation expense

2,662

2,648

5,285

5,200

Provision for income taxes

5,139

4,291

9,132

7,521

Adjusted EBITDA

22,767

19,037

43,038

34,217

Adjusted EBITDA percentage increase

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

(amounts in thousands)

(unaudited)

Reconciliation between GAAP and Non-GAAP sales

growth:

For the three months ended June 30, 2026

Net sales as reported

70,382

Impact of currency exchange rate fluctuations

(352

)

Adjusted net sales

70,030

For the three months ended June 30, 2025

Net sales as reported

64,232

Net impact of divestitures excluding currency

(365

)

Adjusted net sales

63,867

Adjusted net sales increase for the three months ended June 30, 2026

6,163

Reconciliation between GAAP and Non-GAAP sales growth

(excluding catheters):

For the three months ended June 30, 2026

Net sales as reported

70,382

Catheter net sales as reported

(6,895

)

Impact of currency exchange rate fluctuations

(352

)

Adjusted net sales

63,135

For the three months ended June 30, 2025

Net sales as reported

64,232

Catheter net sales as reported

(7,754

)

Adjusted net sales

56,478

Adjusted net sales increase (excluding catheters) for the three months ended June 30,

2026

6,657

Reconciliation between GAAP and Non-GAAP projected sales

growth:

For the three months ending September 30, 2026

Net sales per guidance (midpoint)

67,300

Impact of currency exchange rate fluctuations

489

Adjusted projected net sales

67,789

For the three months ended September 30, 2025

Net sales as reported

61,046

Adjusted net sales

61,046

Adjusted projected net sales increase for the three months ending September 30, 2026

6,743

Reconciliation between GAAP and Non-GAAP projected sales

growth:

For the three months ending December 31, 2026

Net sales per guidance (midpoint)

72,100

Impact of currency exchange rate fluctuations

162

Adjusted projected net sales

72,262

For the three months ended December 31, 2025

Net sales as reported

64,453

Adjusted net sales

64,453

Adjusted projected net sales increase for the three months ending December 31, 2026

7,809

Reconciliation between GAAP and Non-GAAP projected sales

growth:

For the year ending December 31, 2026

Net sales per guidance (midpoint)

276,300

Impact of currency exchange rate fluctuations

(1,749

)

Adjusted projected net sales

274,551

For the year ended December 31, 2025

Net sales as reported

249,602

Net impact of divestitures excluding currency

(1,839

)

Adjusted net sales

247,763

Adjusted projected net sales increase for the year ending December 31, 2026

26,788

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

(amounts in thousands)

(unaudited)

Reconciliation between GAAP and Non-GAAP projected

operating income growth:

For the three months ending September 30, 2026

Operating income per guidance (midpoint)

18,100

Projected operating income

18,100

For the three months ended September 30, 2025

Operating income as reported

20,312

Impact of employee retention credit

(3,380

)

Adjusted operating income

16,932

Adjusted projected operating income increase for the three months ending September 30,

2026

1,168

Reconciliation between GAAP and Non-GAAP projected

operating income growth:

For the year ending December 31, 2026

Operating income per guidance (midpoint)

76,800

Projected operating income

76,800

For the year ended December 31, 2025

Operating income as reported

67,912

Impact of employee retention credit

(3,380

)

Adjusted operating income

64,532

Adjusted projected operating income increase for the year ending December 31, 2026

12,268

Reconciliation between GAAP and Non-GAAP earnings per

share growth:

For the three months ending September 30, 2026

Earnings per share per guidance (midpoint)

0.69

Projected earnings per share

0.69

For the three months ended September 30, 2025

Earnings per share as reported

0.75

Impact of employee retention credit

(0.13

)

Adjusted earnings per share

0.62

Adjusted projected earnings per share increase for the three months ending September 30,

2026

0.07

Reconciliation between GAAP and Non-GAAP earnings per

share growth:

For the year ending December 31, 2026

Earnings per share per guidance (midpoint)

2.89

Projected earnings per share

2.89

For the year ended December 31, 2025

Earnings per share as reported

2.52

Impact of employee retention credit

(0.14

)

Adjusted earnings per share

2.38

Adjusted projected earnings per share increase for the year ending December 31, 2026

0.51

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Document and Entity Information

Aug. 04, 2026

Cover [Abstract]

Entity Registrant Name

LEMAITRE VASCULAR INC

Amendment Flag

false

Entity Central Index Key

0001158895

Document Type

8-K

Document Period End Date

Aug. 04, 2026

Entity File Number

001-33092

Entity Incorporation State Country Code

Entity Tax Identification Number

04-2825458

Entity Address, Address Line One

63 Second Avenue

Entity Address, City or Town

Burlington

Entity Address, State or Province

Entity Address, Postal Zip Code

01803

City Area Code

781

Local Phone Number

221-2266

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Security 12b Title

Common stock, $0.01 par value per share

Trading Symbol

LMAT

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration